PMNHealthcare · BiotechnologyPMN Stock Forecast: ProMIS Neurosciences, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering ProMIS Neurosciences, Inc. hold a median 12-month price target of $34 — +293.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 12 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
PMN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores ProMIS Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (76): Smaller than most of the companies we track.
Accruals (20): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
PMN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PMN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +293.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Guggenheim | Maintains | Buy | $69 → $100 |
| 29 July 2026 | Guggenheim | Maintains | Buy | — |
| 28 July 2026 | Chardan Capital | Maintains | Buy | — |
| 27 July 2026 | Chardan Capital | Initiates | Buy | — |
| 8 July 2026 | Roth Capital | Initiates | Buy | — |
| 30 June 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 1 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 14 July 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 12 May 2025 | Maxim Group | Initiates | Buy | — |
| 1 Apr 2025 | Guggenheim | Reiterates | Buy | — |
| 26 Feb 2025 | Guggenheim | Reiterates | Buy | — |
| 3 Oct 2023 | BTIG | Initiates | Buy | $8.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PMN appears on the weeks it earns a place.
PMN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, ProMIS Neurosciences, Inc. returned −27.8% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PMN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
ProMIS Neurosciences, Inc. (PMN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 7.8×
- Price / sales
- —
- Price / book
- 1.7×
- EV / EBITDA
- −0.8×
Cheaper than 62% of US stocks
Cheaper than 49% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −172.3%
- Return on assets
- −81.1%
- Dividend yield
- 0.0%
Higher than 8% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ProMIS Neurosciences, Inc. (PMN) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ProMIS Neurosciences, Inc. has a market value of $86.2M and an enterprise value of $32.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$42.2M.
Free cash flow in the twelve months to 30 June 2026: −$42.1M.
Trailing P/E: 7.8×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ProMIS Neurosciences, Inc. employs 7 people.
Data provided by Twelve Data
PMN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ProMIS Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about PMN stock
What is the PMN stock price forecast for 2026-2027?
The 8 Wall Street analysts covering ProMIS Neurosciences, Inc. have a median 12-month price target of $34, with estimates ranging from $18 to $98. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PMN stock a buy right now?
Of the 8 analysts covering ProMIS Neurosciences, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ProMIS Neurosciences, Inc. 25 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PMN?
As at 12 Oct 2026, ProMIS Neurosciences, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (76 of 100).
Will PMN stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +293.2% from the last close, and Ticker Nerd's factor model ranks ProMIS Neurosciences, Inc. 25 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PMN stock forecast for 2030?
No analyst covering ProMIS Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $98 over the next 12 months.
How has PMN stock performed over the past year?
ProMIS Neurosciences, Inc. returned -27.8% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ProMIS Neurosciences, Inc. do?
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases and other misfolded protein disorders.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases and other misfolded protein disorders. The company works on treatments designed to selectively target toxic protein species linked to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, and multiple system atrophy. Its research platform combines protein biology, physics, and computational methods to identify disease-specific epitopes on misfolded proteins, supporting a pipeline of precision medicine candidates. ProMIS Neurosciences also develops therapies aimed at other central nervous system disorders, reflecting its broader focus on protein misfolding biology in neurological disease. Headquartered in Toronto, Canada, with offices in Cambridge, Massachusetts, ProMIS Neurosciences plays a specialized role in the biotechnology market as a developer of targeted approaches for complex neurological conditions.
CEO Mr. Neil K. Warma M.B.A. · 7 employees · Canada · https://www.promisneurosciences.com